Fasting blood glucose, glycaemic control and prostate cancer risk in the Finnish Randomized Study of Screening for Prostate Cancer

Teemu J. Murtola,Ville JY Vihervuori,Jorma Lahtela,Kirsi Talala,Kimmo Taari,Teuvo LJ Tammela,Anssi Auvinen
DOI: https://doi.org/10.1038/s41416-018-0055-4
IF: 9.075
2018-03-22
British Journal of Cancer
Abstract:BackgroundDiabetic men have lowered overall risk of prostate cancer (PCa), but the role of hyperglycaemia is unclear. In this cohort study, we estimated PCa risk among men with diabetic fasting blood glucose level.MethodsParticipants of the Finnish Randomized Study of Screening for Prostate Cancer (FinRSPC) were linked to laboratory database for information on glucose measurements since 1978. The data were available for 17,860 men. Based on the average yearly level, the men were categorised as normoglycaemic, prediabetic, or diabetic. Median follow-up was 14.7 years. Multivariable-adjusted Cox regression was used to calculate hazard ratios (HRs) and 95% confidence intervals (95% CIs) for prostate cancer overall and separately by Gleason grade and metastatic stage.ResultsIn total 1,663 PCa cases were diagnosed. Compared to normoglycaemic men, those men with diabetic blood glucose level had increased risk of PCa (HR 1.52; 95% CI 1.31–1.75). The risk increase was observed for all tumour grades, and persisted for a decade afterwards. Antidiabetic drug use removed the risk association. Limitations include absence of information on lifestyle factors and limited information on BMI.ConclusionsUntreated diabetic fasting blood glucose level may be a prostate cancer risk factor.
oncology
What problem does this paper attempt to address?